Abstract
Erythropoiesis-stimulating agents (ESAs) are approved worldwide for treating anemia in cancer patients receiving chemotherapy. ESA-safety issues include thromboembolic events and there have been concerns about a possible induction of disease progression or increased mortality in cancer patients treated with these agents. This chapter discusses available evidence regarding this question. Clinical data and preclinical studies provide no convincing evidence that ESAs increase any risk related to the patient’s cancer when used within label. Assessment and definition of disease progression vary across studies, and preclinical work has often been conducted with inadequate methodology.
Keywords: Disease progression, erythropoietin receptor, erythropoiesisstimulating agents.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development